Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

THC drug tested as new treatment for COPD breathlessness

NCT ID NCT06473701

First seen Apr 22, 2026 · Last updated May 26, 2026 · Updated 9 times

Summary

This study tests whether dronabinol, a synthetic THC (the active compound in cannabis), can reduce severe breathlessness in people with advanced COPD. About 30 adults with very severe COPD who still struggle to breathe despite standard treatments will receive either dronabinol or a placebo in a crossover design. The goal is to see if the drug improves daily comfort and activity levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Vejle Hospital - A part of Lillebaelt Hospital

    RECRUITING

    Vejle, Region Syddanmark, 7100, Denmark

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.